We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Mediclinic International Plc | LSE:MDC | London | Ordinary Share | GB00B8HX8Z88 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 501.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2021 to Apr 2024
TIDMMDC
RNS Number : 6603G
Mediclinic International plc
28 July 2021
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
South African income tax number: 9432434182
("Mediclinic", the "Company", or the "Group")
28 July 2021
ANNOUNCEMENT OF THE 2021 ANNUAL GENERAL MEETING POLL RESULTS
Mediclinic announces that at its annual general meeting ("AGM") held on 27 July 2021, all resolutions set out in the notice of the AGM were passed by the requisite majority of votes by shareholders by way of poll. The results of the poll for each resolution were as follows:
Hot Features
Premium
Total % of Votes for % Votes against % Votes
shares issued withheld
voted share
capital
voted
Ordinary resolutions
------------------------------- --------- --------- ---------- -------- -------------- ------- ----------
To receive the
Company's annual 667 565 667 559
1. accounts and reports 118 90.55% 483 100.00% 5 635 0.00% 499 627
------------------------------- --------- --------- ---------- -------- -------------- ------- ----------
To approve the
Directors' Remuneration 667 830 649 003
2 Report 071 90.58% 589 97.18% 18 826 482 2.82% 234 674
------------------------------- --------- --------- ---------- -------- -------------- ------- ----------
To elect Mr Steve 667 829 667 659
3. Weiner as a director 927 90.58% 971 99.97% 169 956 0.03% 234 818
------------------------------- --------- --------- ---------- -------- -------------- ------- ----------
To re-elect Dame
Inga Beale as a 667 829 667 647
4. director 927 90.58% 423 99.97% 182 504 0.03% 234 818
------------------------------- --------- --------- ---------- -------- -------------- ------- ----------
To re-elect Dr
Ronnie van der 667 829 667 238
5. Merwe as a director 927 90.58% 556 99.91% 591 371 0.09% 234 818
------------------------------- --------- --------- ---------- -------- -------------- ------- ----------
To re-elect Mr
Jurgens Myburgh 667 829 667 524
6. as a director 927 90.58% 108 99.95% 305 819 0.05% 234 818
------------------------------- --------- --------- ---------- -------- -------------- ------- ----------
To re-elect Mr
Alan Grieve as 667 828 667 259
7. a director 971 90.58% 291 99.91% 569 680 0.09% 235 774
------------------------------- --------- --------- ---------- -------- -------------- ------- ----------
To re-elect Dr
Muhadditha Al Hashimi 667 829 667 658
8. as a director 671 90.58% 508 99.97% 171 163 0.03% 235 074
------------------------------- --------- --------- ---------- -------- -------------- ------- ----------
To re-elect Mr
Jannie Durand as 667 829 642 538
9. a director 926 90.58% 343 96.21% 25 291 583 3.79% 234 819
------------------------------- --------- --------- ---------- -------- -------------- ------- ----------
To re-elect Dr
Felicity Harvey 667 829 667 259
10. as a director 927 90.58% 550 99.91% 570 377 0.09% 234 818
------------------------------- --------- --------- ---------- -------- -------------- ------- ----------
To re-elect Mr
Danie Meintjes 667 829 650 797
11. as a director 671 90.58% 104 97.45% 17 032 567 2.55% 235 074
------------------------------- --------- --------- ---------- -------- -------------- ------- ----------
To re-elect Dr
Anja Oswald as 667 829 667 259
12. a Director 927 90.58% 550 99.91% 570 377 0.09% 234 818
------------------------------- --------- --------- ---------- -------- -------------- ------- ----------
To re-elect Mr
Trevor Petersen 667 829 667 377
13. as a director 927 90.58% 501 99.93% 452 426 0.07% 234 818
------------------------------- --------- --------- ---------- -------- -------------- ------- ----------
To re-elect Mr
Tom Singer as a 667 829 667 658
14. director 927 90.58% 761 99.97% 171 166 0.03% 234 818
------------------------------- --------- --------- ---------- -------- -------------- ------- ----------
To re-appoint
PricewaterhouseCoopers
LLP as the Company's 667 829 662 327
15. auditor 267 90.58% 424 99.18% 5 501 843 0.82% 235 478
------------------------------- --------- --------- ---------- -------- -------------- ------- ----------
To authorise the
Audit and Risk
Committee to determine 667 830 667 422
16. the auditor's remuneration 127 90.58% 090 99.94% 408 037 0.06% 234 618
------------------------------- --------- --------- ---------- -------- -------------- ------- ----------
To authorise political 667 826 552 878 114 947
17. donations 024 90.58% 546 82.79% 478 17.21% 238 721
------------------------------- --------- --------- ---------- -------- -------------- ------- ----------
To authorise the
directors to allot 667 829 531 586 136 243
18. ordinary shares 911 90.58% 682 79.60% 229 20.40% 234 834
------------------------------- --------- --------- ---------- -------- -------------- ------- ----------
Special resolutions
------------------------------- --------- --------- ---------- -------- -------------- ------- ----------
To authorise the
directors to dis-apply
statutory pre-emption 667 828 546 934 120 893
19. rights 162 90.58% 805 81.90% 357 18.10% 236 583
------------------------------- --------- --------- ---------- -------- -------------- ------- ----------
To authorise the
directors to dis-apply
pre-emption rights
for purposes of
acquisitions or 667 828 553 250 114 578
20. capital investments 412 90.58% 080 82.84% 332 17.16% 236 333
------------------------------- --------- --------- ---------- -------- -------------- ------- ----------
To approve the
reduction in minimum
notice period for
general meetings
(other than annual 667 705 632 190
21. general meetings) 486 90.57% 749 94.68% 35 514 737 5.32% 359 259
------------------------------- --------- --------- ---------- -------- -------------- ------- ----------
Votes of shareholders excluding the controlling shareholder on election and re-election of independent non-executive directors
Ordinary Resolutions Total % of Votes for % Votes against % Votes
shares issued withheld
voted share
capital
voted
To elect Mr Steve 339 332 339 162
3. Weiner as a director 039 83.02% 083 99.95% 169 956 0.05% 234 818
----------------------- -------- --------- ---------- ------- -------------- ------ ----------
To re-elect Dame 339 332 339 149
4. Inga as a director 039 83.02% 535 99.95% 182 504 0.05% 234 818
----------------------- -------- --------- ---------- ------- -------------- ------ ----------
To re-elect Mr
Alan Grieve as 339 331 338 761
7. a Director 083 83.02% 403 99.83% 569 680 0.17% 235 774
----------------------- -------- --------- ---------- ------- -------------- ------ ----------
To re-elect Dr
Muhadditha Al Hashimi 339 331 339 160
8. as a director 783 83.02% 620 99.95% 171 163 0.05% 235 074
----------------------- -------- --------- ---------- ------- -------------- ------ ----------
To re-elect Dr
Felicity Harvey 339 332 338 761
10. as a director 039 83.02% 662 99.83% 570 377 0.17% 234 818
----------------------- -------- --------- ---------- ------- -------------- ------ ----------
To re-elect Dr
Anja Oswald as 339 332 338 761
12. a director 039 83.02% 662 99.83% 570 377 0.17% 234 818
----------------------- -------- --------- ---------- ------- -------------- ------ ----------
To re-elect Mr
Trevor Petersen 339 332 338 879
13. as a director 039 83.02% 613 99.87% 452 426 0.13% 234 818
----------------------- -------- --------- ---------- ------- -------------- ------ ----------
To re-elect Mr
Tom Singer as a 339 332 339 160
14. director 039 83.02% 873 99.95% 171 166 0.05% 234 818
----------------------- -------- --------- ---------- ------- -------------- ------ ----------
Notes:
1. Any proxy appointments giving discretion to the Chair of the meeting
have been included in the "For" total.
2. A vote "Withheld" is not a vote in law and is not counted in the
calculation of the votes "For" or "Against" a resolution.
3. The Company's total ordinary shares in issue (total voting rights)
as at 27 July 2021 was 737 243 810 ordinary shares of 10 pence
each. Ordinary shareholders are entitled to one vote per ordinary
share held.
4. As the Company has a controlling shareholder, Remgro Limited, as
defined in the Financial Conduct Authority's Listing Rules ("Listing
Rules"), each resolution to elect an independent non-executive
director (Resolutions 3, 4, 7, 8, 10, 12, 13, and 14) have under
Listing Rule 9.2.2E been approved by a majority of the votes cast
by: (a) the shareholders of the Company as a whole; and (b) the
independent shareholders of the Company, that is, all the shareholders
entitled to vote on each resolution, excluding the controlling
shareholder.
Statement regarding voting results
The Board notes that while Resolution 18 was passed with a majority of 79.60%, a number of our shareholders opposed this resolution.
The views of all shareholders are important to Mediclinic. The Company will reflect carefully on the feedback already received and continue to engage with shareholders, to gain a greater understanding of the reasons for their views.
Mediclinic will publish an update on that engagement within six months of the AGM. In the interim, the Board notes that, the voting outcome on Resolution 18 reflects the prevailing institutional voting policies in South Africa. As a company with a primary premium listing on the London Stock Exchange ("LSE"), the Board considers it appropriate to seek authorities in line with the UK Investment Association's Share Capital Management Guidelines, which provide the Company with greater flexibility to respond to market developments and business opportunities as they arise. Many of the Group's South African institutional investors understand the Company's position but some operate under mandates that do not allow them to support this level of flexibility. Mediclinic will continue to engage with its South African shareholders on this topic; however in view of the marked differences between UK and South African market practice in this area, it is likely that there will continue to be significant votes against this resolution.
In accordance with paragraph 9.6.2 of the Listing Rules, a copy of the resolutions passed at the AGM is being submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
The complete poll results and details of proxy votes lodged before the AGM will be available shortly on the Investor Relations section of the Company's website at https://investor.mediclinic.com/regulatory-news.
About Mediclinic International plc
Mediclinic is a diversified international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates ("UAE").
The Group's core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for all their healthcare needs.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.
At 31 March 2021, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health facilities, 18 day case clinics and 18 outpatient clinics. Hirslanden operated 17 hospitals and four day case clinics in Switzerland with more than 1 900 inpatient beds; Mediclinic Southern Africa operations included 50 hospitals (three of which in Namibia), five sub-acute hospitals, two mental health facilities and 12 day case clinics (four of which operated by Intercare) across South Africa, and around 8 600 inpatient beds; and Mediclinic Middle East operated seven hospitals, two day case clinics and 18 outpatient clinics with more than 900 inpatient beds in the UAE. In addition, under management contracts, Mediclinic Middle East operates one hospital in Abu Dhabi and will open a 200-bed hospital in the Kingdom of Saudi Arabia in mid-2022.
The Company's primary listing is on the LSE in the UK, with secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)333 300 1930
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Ben Atwell/Ciara Martin - United Kingdom
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000
Registered address: 6(th) Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker (United Kingdom): Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RAGSEWFIWEFSELW
(END) Dow Jones Newswires
July 28, 2021 02:00 ET (06:00 GMT)
1 Year Mediclinic Chart |
1 Month Mediclinic Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
